[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"leptospirosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:leptospirosis":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,78,177,197,219,242,291],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100640589","ex-vivo-study-of-leukocyte-responses-in-the-blood-of-patients-with-leptospirosis-and-ex-vivo-testing-of-a-new-host-targeted-therapeutic-strategy-to-restore-phagocytosis-of-leptospira-100640589",false,"NCT07611591","Ex Vivo Study of Leukocyte Responses in the Blood of Patients With Leptospirosis and ex Vivo Testing of a New Host-targeted Therapeutic Strategy to Restore Phagocytosis of Leptospira","NEUTROLEPTO-NC","Inclusion Criteria:\n\n* Be of legal age (18 years or older at the time of enrollment),\n* Be capable of understanding and providing informed consent,\n* Have received information and provided written consent,\n* Be enrolled in a social security program.\n* Be suspected of having leptospirosis\n\nExclusion Criteria:\n\n* With a chronic inflammatory disease,\n* Whose health condition is incompatible with additional blood draws totaling 40 ml,\n* Receiving concomitant treatment with antibiotics and\u002For anti-inflammatory drugs, or undergoing medical treatment incompatible with the study's objectives,\n* Pregnant or breastfeeding women.\n* Hospitalized or having undergone surgery within the previous 7 days","ALL","18 Years",{"count":19,"type":20},70,"ESTIMATED","OBSERVATIONAL","Leptospirosis is a neglected zoonosis caused by pathogenic spirochetes of the genus \\*Leptospira\\*, occurring mainly in humid tropical and subtropical regions. With over one million cases and \\~60,000 deaths annually, it is among the most dangerous bacterial zoonoses worldwide. Its nonspecific onset-fever, headache, myalgia-mimics influenza, dengue, and other acute febrile illnesses, making diagnosis difficult. Delayed antibiotic treatment can lead to severe forms (in \\~10% of cases) characterized by hemorrhage and multi-organ failure. In 2023, New Caledonia reported 152 cases, with 85% hospitalized and a 2.6% mortality rate.\n\nThis study aims to characterize the human host response and improve patient management. \\*Leptospira\\* evades innate immunity, triggering a strong anti-inflammatory IL-10 response and potentially ineffective phagocytosis. However, the WHO-recommended β-lactam antibiotics induce a Jarisch-Herxheimer reaction (JHR)-an acute inflammatory response occurring within hours of treatment-in over 50% of patients (LEPJAR study, PMID:40986630), the impact of which on phagocytosis is unknown.The NEUTROLEPTO study will be conducted in New Caledonia (NC) in patients with or without leptospirosis. Clinical and biological data will be collected at the time of suspected infection and 3 hours after antibiotic administration. Specifically, immune responses will be assessed through cytokine profiling and blood cell phenotyping, as well as by transcriptome analysis of infected patients before and after antibiotic treatment.",[24,25],"Leptospirosis","Jarisch Herxheimer Reaction",[27,25,28,29],"leptospirosis","Inflammation","ß-lactams antibiotics","NOT_YET_RECRUITING","2026-05-21",{"date":33,"type":34},"2026-05-28","ACTUAL",{"date":36,"type":20},"2026-07-01",{"date":38,"type":20},"2029-07-01",{"name":40,"class":41},"Institut Pasteur","INDUSTRY",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100602761","phase-2-preventive-strategies-for-early-and-late-complications-of-leptospirosis-100602761","NCT07127718","Preventive Strategies for Early and Late Complications of Leptospirosis","Decreasing Leptospirosis Emergence Through Prognosis and Treatment Optimization (DeLEPTO) Project 1: Preventive Strategies for Early and Late Complications of Leptospirosis","Inclusion Criteria:\n\n* Subjects with acute fever (38ºC for at least two days) and at least one of the following: myalgia, jaundice, headache, meningeal irritation, oliguria, conjunctival suffusion\n* Who have a microscopic agglutination test (MAT) that indicates a single serum sample MAT titer greater than or equal to 1:400\n* Or a positive result for the latex agglutination test or a repeat test after seven days\n* Or a positive result for Leptospira IgG\u002FIgM lateral flow immunochromatographic test (ICT) or a repeat test within 3-14 days after the baseline test\n* Or a positive result for Leptospira polymerase chain reaction (PCR)\n* Or a positive blood culture of leptospira WITHOUT the complication specified in a subgroup of interest\n* PPTTRT\u002FPPTCONV: Not requiring ventilator support\n* HPTRT\u002FHPCONV: Dialysis Requiring Acute Kidney Injury. Defined as KDIGO Acute Kidney Injury Stage 3 or requiring renal replacement therapy to correct intractable acidosis, electrolyte abnormality, or over uremic encephalopathy or pericarditis\n* HPTRT\u002FHPCONV: Vasopressor Requiring - The subject must have received intravenous fluid resuscitation of a minimum of 30ml\u002Fkg within 24 hours of eligibility and still with hypotension (blood pressure less than 90\u002F60, MAP less than 65) requiring vasopressor support\n* HPTRT\u002FHPCONV: SOFA SCORE less than 15\n* ECMO: A Murray score of greater than or equal to 2.75\n\nExclusion Criteria:\n\n* Previous diagnosis of chronic kidney disease or on maintenance dialysis\n* Previous diagnoses of diseases associated with hemoptysis, such as bronchiectasis\n* Blood dyscrasias, malignancy, severe heart disease, HIV, cavitary PTB, Cirrhosis by ultrasound, severe malnutrition (Weight of less than 35kg)\n* Post cardiac arrest or those with GCS less than 8 at present. Participant has had chest compressions or CPR\n* Pregnancy\n* PPTTRT\u002FPPTCONV: Requiring emergent dialyses\n* PPTTRT\u002FPPTCONV: Significant lung pathology as defined by P\u002FF ratio less than 300, or obvious respiratory distress\n* PPTTRT\u002FPPTCONV: Presence of severe neurological symptoms\n* PPTTRT\u002FPPTCONV: Hypotension (or need for vasopressor support)\n* PPTTRT\u002FPPTCONV: Ongoing hemodynamic instability","60 Years",{"count":51,"type":20},678,"INTERVENTIONAL",[54],"PHASE2","The goal of this clinical trial is to learn if complement factor I (CFI) works to predict development of complications in participants with leptospirosis. It will also learn if plasma transfusion, hemoperfusion, and extracorporeal membrane oxygenation works to treat participants with leptospirosis. The main questions it aims to answer are:\n\n* Does a low level of CFI predict the development of lung damage in participants with leptospirosis?\n* Does plasma tranfusion lower the chances of participants getting lung damage from leptospirosis?\n* Does hemoperfusion work to remove harmful materials from the blood of participants with leptospirosis?\n* Does extracorporeal membrane oxygenation increase the chance of survival in participants with lung damage?\n\nResearchers will compare plasma tranfusion and hemoperfusion to conventional therapy (standard of care for leptospirosis, including antibiotics, fluids, and other treatment that the doctor deems necessary) to see if these novel therapies work to treat leptospirosis.\n\nParticipants will:\n\n* Give blood samples for the study of CFI\n* Receive conventional therapy and\u002For plasma transfusion for 4 times in 2 days, OR\n* Receive conventional therapy and\u002For hemoperfusion for at least 3 days, AND\u002FOR\n* Receive extracorporeal membrane oxygenation if their condition worsens",[24],[27,58,59,60,61,62,63,64,65],"plasma transfusion","hemoperfusion","extracorporeal membrane oxygenation","complement factor I","CFI","complications","renal complications","pulmonary complications","RECRUITING","2026-04-07",{"date":69,"type":34},"2026-04-13",{"date":71,"type":34},"2024-04-12",{"date":73,"type":20},"2027-03",{"name":75,"class":76},"National Kidney and Transplant Institute, Philippines","OTHER",3,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":16,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":90,"conditions":91,"keywords":149,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":176},"100620537","risk-assessment-of-community-spread-of-multiple-endemic-infectious-diseases-in-a-one-health-perspective-100620537","NCT07358910","Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","RACSMEI","Inclusion Criteria:\n\n* Residency in the village for more than 6 months;\n* Age between 2 and 75 years old at the time of inclusion;\n* For adults: provision of written consent;\n* For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;\n\nExclusion Criteria:\n\n* Unable to understand or consent;\n* Under guardianship or deprived of liberty;\n* Medical conditions that impede survey participation;\n* Refusal to participate in the study.",true,"2 Years","75 Years",{"count":89,"type":20},10000,"RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.\n\nRACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.\n\nMathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.",[92,93,94,95,96,97,98,99,100,101,102,103,24,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148],"Dengue","Chikungunya","Zika Virus Infection","Japanese Encephalitis","West Nile Virus","Tick-borne Encephalitis (TBE)","Severe Fever With Thrombocytopenia Syndrome","Nipah Virus Infection","Hantavirus Infections","Hepatitis E","Brucellosis","Q Fever","Melioidosis","Influenza A and B","Malaria","Yellow Fever","Mayaro Fever","Usutu Virus Infection","Oropouche Fever","Rift Valley Fever","Arenavirus Infections","Measles","Mumps","Rubella","Human Papilloma Virus (HPV)","Rotavirus Disease","Pertussis","Diphteria","Tetanus","Varicella","Hepatitis A","Norovirus Infections","Enterovirus","Adenovirus","Rhinovirus","Parvovirus","Respiratory Syncytial Virus (RSV)","Cytomegalovirus","Epstein Barr Virus","Salmonella Typhi","Vibrio Cholerae","Legionella Pneumophila Pneumonia","Mycoplasma","Chlamydia","Lymphatic Filariasis","Toxoplasma Gondii","Giardiasis","Entamoeba Histolytica","Leishmaniasis","Strongyloides Stercoralis Infection","Ascaris Lumbricoides","Trichuris Trichiura","Clonorchis Sinensis","Opisthorchis Viverrini","Schistosomiasis","Streptococcus Pneumoniae","Meningitis",[150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166],"Infectious disease","One Health","Population-based survey","Nationally representative survey","Seroepidemiology","Multiplex serology","Seroprevalence","Vector-borne diseases","Zoonoses","Vaccine-preventable diseases","Neglected tropical diseases","Transmission dynamics","Force of infection","Mathematical modelling","Spatial epidemiology","Precision public health","Cambodia","2026-01-14",{"date":169,"type":34},"2026-01-22",{"date":171,"type":34},"2025-12-18",{"date":173,"type":20},"2027-09-30",{"name":175,"class":76},"Institut Pasteur du Cambodge",1,{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":176},"100384666","leptospirosis-registry---leptoscope-100384666","NCT04288674","Leptospirosis Registry - LeptoScope","Leptoscope","Inclusion Criteria:\n\n* Cultural, serological, molecular or histological evidence of invasive leptospirosis diseases\n* Clinical signs of disseminated leptospirosis disease without cultural, serological, molecular or histological evidence\n* Case controls: Matching procedures for controls: Particularly, case controls will be included at the same hospitals that conduced cases based on matching of demographics, underlying diseases and duration of hospitalization (i.e. one control per case, both in the same hospital).\n\nExclusion Criteria:\n\n* Colonization or other non-invasive infection\n* Cultural, serological, molecular or histological evidence without dissemination",{"count":185,"type":20},200,"Leptospirosis is a worldwide zoonotic diseases caused by pathogenic Leptospira spp. Human are accidental hosts, who acquired infections after exposition to animal urine, contaminated water or soil, infected tissue. Incidence of invasive leptospirosis disease causing acute kidney injury, acute respiratory distress syndrome (ARDS), myocarditis, hepatic dysfunction, hemorrhage and multi-organ failure, is globally increasing and there have been frequent outbreak situation throughout the world. Due to increasing outbreak situations and globally chances in species distributions, a worldwide surveillance in epidemiology and species distribution is urgently needed. The objective of the Leptospirosis Registry - LeptoScope is to overcome the lack knowledge on epidemiology, clinical course, prognostic factors and molecular characteristics for invasive leptospirosis disease.",[24],"2025-12-09",{"date":190,"type":34},"2025-12-17",{"date":192,"type":34},"2020-03-04",{"date":194,"type":20},"2030-12",{"name":196,"class":76},"University of Cologne",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":52,"phases":206,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":176},"100471949","leptospirosis-care-bundle-study-100471949","NCT05425524","Leptospirosis Care Bundle Study","Leptospirosis Care Bundle Study: A Randomized Controlled Trial","Inclusion Criteria:\n\n* age \\> 18 years\n* Suspicious Leptospirosis including body temperature \\> 38 celcius, Severe myalgia, and exposure to reservoir hospital of flood water.\n* Calf muscle tenderness\n* Conjunctival suffusion\n* Anuria or oliguria and\u002For proteinuria\n* Jaundice\n* Hemorrhagic manifestations (pulmonary and intestine)\n* Meningeal irritation\n* Nausea, vomiting, abdominal pain, diarrhea.\n* Admitted in hospital\n\nExclusion Criteria:\n\n* other infectious disease\n* pregnancy",{"count":205,"type":20},300,[207],"NA","So in management of Leptospirosis patients There really is no another approach to treatment. The importance of the problem was acknowledged by the researchers. As a result, this study was performed in order to The Leptospirosis Care Bundle has been used, and has been proved that its use can reduce the risk of acute renal failure.",[24],"2025-08-04",{"date":212,"type":34},"2025-08-07",{"date":214,"type":34},"2019-10-01",{"date":216,"type":20},"2026-12-31",{"name":218,"class":76},"Chulalongkorn University",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":85,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":52,"phases":228,"briefSummary":229,"conditions":230,"keywords":231,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":241,"locationsCount":4},"100588778","characterizing-the-host-response-to-leptospirosis-for-better-diagnosis-and-prognosis---nihfi-100588778","NCT06945822","Characterizing the Host Response to Leptospirosis for Better Diagnosis and Prognosis - NIHFI","NIHFI","Inclusion Criteria:\n\nFor all participants :\n\n* Be able to consent,\n* Have received information and given written consent,\n* Be covered by a social security plan. For groups 1 \\& 2: febrile individuals\n* Have suspected leptospirosis associated with fever (axillary temperature over 38°C) and a clinical picture of suspected leptospirosis (myalgia, headache...). After inclusion, febrile participants will be divided into 2 groups when the diagnosis of leptospirosis is confirmed. The 2 groups are defined as follows:\n\nGroup 1: leptospirosis\n\n\\- Individual with leptospirosis confirmed by PCR, MAT, or isolation (2013 Center For Disease Control and Prevention (CDC) laboratory criteria for a confirmed diagnosis).\n\nGroup 2: MFA, with absence of leptospirosis\n\nAll individuals in Group 2 will have tests as part of their MFA diagnosis, depending on their symptomatology:\n\n* Other acute bacterial zoonotic infection: Infection confirmed by paired serology or double PCR (2 targets).\n* Acute arboviral infection: dengue, chikungunya or Zika virus confirmed by CDC Trioplex PCR in a patient with consistent serology or positive 2nd target PCR.\n* Acute respiratory viral infection: Viral agent confirmed by MFA multiplex PCR. For group 3: healthy individuals\n* Apyretic individuals, no symptoms of infection or inflammatory disease in the last 28 days.\n\nExclusion Criteria:\n\nindividuals :\n\n* with a chronic inflammatory disease,\n* undergoing concomitant antibiotic and\u002For anti-inflammatory treatment, or under medical care incompatible with the purpose of the study,\n* pregnant or breast-feeding women,\n* persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care and persons admitted to a health or social institution,\n* Adults subject to a legal protection measure or unable to express their consent\n* Persons not affiliated to a social security scheme or beneficiaries of such a scheme\n* Hospitalized for more than 48 hours,\n* Hospitalized or operated on in the previous 7 days.",{"count":227,"type":20},450,[207],"Leptospirosis is a zoonosis found worldwide, but particularly in humid subtropical and tropical zones. It is caused by pathogenic bacteria of the Leptospira species of the spirochete family. It is estimated that there are over a million cases of leptospirosis worldwide each year, with 60,000 deaths. These figures place leptospirosis among the most dangerous bacterial zoonoses in the world.\n\nThe disease affects the most disadvantaged populations, and also inflicts its burden on domestic and farm animals. To this day, however, leptospirosis remains a neglected disease, poorly understood because it has been little studied.\n\nHuman leptospirosis initially presents as a febrile syndrome, with fever, headache, myalgia and joint pain. These symptoms are very similar to those observed in influenza, dengue fever and other acute febrile illnesses, making diagnosis very difficult.\n\nDelayed initiation of antibiotic therapy, a treatment recommended by the WHO, is associated with the development of severe forms of leptospirosis. Indeed, in 10% of cases, leptospirosis evolves into severe forms, which are still poorly described, but which result in haemorrhage, multivisceral failure (lungs, kidneys, liver) and a drastic increase in the case-fatality rate. In 2023, 152 cases of leptospirosis were reported in New Caledonia. Of these, 130 people (85%) were hospitalized and 4 deaths were recorded (2.6%).\n\nFor patients suffering from leptospirosis, it is therefore important to be able to make the diagnosis quickly, ideally as soon as symptoms appear. It is also crucial to be able to monitor, or even prevent, the development of severe forms of the disease, to ensure optimal patient care.",[24],[232,233,234],"biomarkers","New Caledonia","infection","2025-04-18",{"date":237,"type":34},"2025-04-25",{"date":239,"type":20},"2025-06-01",{"date":38,"type":20},{"name":40,"class":41},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":52,"phases":252,"briefSummary":253,"conditions":254,"keywords":267,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":176},"100582154","serological-measurement-of-montpellier-professionals-contacts-with-infectious-agents-responsible-for-animal-borne-diseases-100582154","NCT06859619","Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases","Seroprevalence of Zoonotic and Arboviral Emerging Infections in Exposed Agents from the City of Montpellier: a Transversal Study.","SEZAM","Inclusion Criteria:\n\n* Age 18 or over\n* Consultant in an infectious diseases department\n* Have given written consent to participate in the study\n* Working for the City or Metropolis of Montpellier in the Zoo, Espaces Vert or Ecolothèque departments.\n\nExclusion Criteria:\n\n* \\- Pregnant and breast-feeding women\n* Persons benefiting from legal protection measures (guardianship, curatorship, safeguard of justice)\n* Participants who are not fluent in French and who do not have a support person capable of reading French.\n* Persons unable to express their consent.\n* Persons participating in another research project with an exclusion period still in progress.\n* Persons not affiliated to a social security scheme or not benefiting from such a scheme.",{"count":251,"type":20},183,[207],"Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments). Most of these diseases are found in certain tropical zones, but global warming and increased international trade are modifying their geographical distribution, with a gradual trend towards temperate regions. A number of these pathogens have already been detected in Occitania, including dengue fever, West Nile, leishmaniasis and Q fever. Given the region's high mosquito population and favorable climatic conditions, other zoonoses have a strong potential to appear in the region, or may already be circulating at a low level. The study focuses on 18 pathogens selected for their potential to emerge and establish themselves in the Occitanie region: Leishmaniasis, Leptospirosis, Brucellosis, Q fever, Rickettsiosis, Tularemia, Psittacosis, Lyme disease, Tick-borne encephalitis, Hantavirus, Hepatitis E virus, Dengue virus, Zika virus, Chikungunya virus, West-Nile virus, Usutu virus, Toscana virus, Crimean-Congo haemorrhagic fever virus.\n\nThe aim of the study is to find out whether patients have antibodies against these infectious agents, which would indicate that they have been exposed to them in the past, even in the absence of symptoms.\n\nDescribing the circulation of these pathogens will enable to implement appropriate public health measures to avoid the risk of epidemics (mosquito control, informing professionals, etc.), as well as to assess the risk incurred in the workplace and have this risk recognized by the healthcare system.",[140,24,102,103,255,256,257,258,259,260,101,261,262,263,96,264,265,266],"Rickettsiosis","Tularemia","Psittacosis","Lyme Disease","Tick-borne Encephalitis","Hantaviral Infection Nos","Dengue Virus","Zika Virus","Chikungunya Virus Infection","Usutu Virus","Toscana Virus","Crimean-Congo Haemorrhagic Fever Virus",[268,24,102,269,270,271,272,273,274,275,276,277,278,279,256,257,280,281],"Leishmaniasis,","Zika virus","Q fever, Rickettsiosis","Lyme disease","Tick-borne encephaliti","Hantavirus","Hepatitis E virus","Dengue virus","Chikungunya virus","West-Nile virus","Usutu virus","Toscana virus","Crimean-Congo haemorrhagic fever virus","epidemiology","2025-02-27",{"date":284,"type":34},"2025-03-05",{"date":286,"type":20},"2025-03-03",{"date":288,"type":20},"2025-10-03",{"name":290,"class":76},"University Hospital, Montpellier",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":52,"phases":300,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":312},"100472812","chronic-post-leptospirosis-manifestations-in-reunion-100472812","NCT05436756","Chronic Post-leptospirosis Manifestations in Reunion","LEPTONIC","Inclusion Criteria:\n\n* Adult or child subjects having been included in the COLEPT cohort with confirmed leptospirosis Where\n* Adult subjects or children hospitalized for leptospirosis confirmed within 12-18 months before LEPTONIC inclusion;\n* Be resident in Reunion\n* Ability to answer a telephone questionnaire\n* Benefit from a social security scheme\n\nExclusion Criteria:\n\n* Refusal of participation by the patient or his entourage if the patient is physically unable to give his opinion (coma, resuscitation, etc.).\n* Exclusion or premature termination of participation in the COLEPT cohort\n* Patient under judicial safeguard, guardianship or curatorship, under activated future protection mandate and family authorization",{"count":299,"type":20},198,[207],"Leptospirosis is a zoonosis caused by spirochetes, pathogenic bacteria of the genus Leptospira. It is transmitted to humans through mucocutaneous lesions by contact with water or soil contaminated by the urine of animal reservoirs (rats, dogs, pigs, cattle, etc.). Exposure to fresh water, contact with water or soil contaminated with animal waste are the main risk factors.\n\nThis disease is an important public health problem in humans and animals. The annual global incidence is estimated at nearly one million cases with a mortality of 5 to 10% for all cases combined and up to 50% in the event of multi-organ failure. The number of cases is growing and the disease is probably more widespread because it is underdiagnosed. The incidence could increase further in the coming decades due to climate change and rapid urbanization.\n\nIn the Overseas Departments and Regions (DROM), it is an endemic condition and its incidence is 10 to 100 times higher than that of mainland France, mainly for climatic reasons. In Réunion, the disease is notifiable with a number of notified cases ranging from 70 to more than 100 cases per year in recent years. Nearly 90% of confirmed cases were hospitalized and more than a third of patients stayed in intensive care.\n\nRecently, a multicenter cohort of patients hospitalized with leptospirosis in La Réunion (COLEPT) was funded by Inserm to identify the severity factors of the disease in patients hospitalized in one of the 4 hospitals on the island. A community of hospital practitioners active on this theme has been identified and constitutes the core of this project. The main objective of the study, the inclusions of which began in January 2020, is to identify the severity factors of leptospirosis in Reunion. Patient follow-up is planned for up to 1 year with 2 medical visits at 1 month and 1 year and 2 telephone interviews on quality of life.\n\nThe disease is generally perceived as a purely acute condition with a rapid ad integrum recovery. Nevertheless, the evolution at a distance has been little evaluated. A few publications report complications and elements of chronicity in the medium\u002Flong term (\\>1 year) which would require monitoring these patients over a longer period. Regarding these potential chronic manifestations, they may be chronic fatigue, uveitis, renal failure, chronic renal carriage with urinary excretion of leptospires, myalgia and muscle weakness, headaches, malaise but also cardiac or neurological manifestations. A Dutch study conducted on subjects with confirmed diagnosis reported 30% of patients with chronic post-leptospirosis symptoms which persisted in 21% of subjects more than 24 months after infection, but very few data are available on the chronic forms.\n\nThe objective will be to study the future of patients beyond 1 year of infection in clinical and serological terms, but also in terms of quality of life, use of alternative medicines and complementary and health literacy profiles.",[24],"2023-08-29",{"date":305,"type":34},"2023-08-31",{"date":307,"type":34},"2022-07-25",{"date":309,"type":20},"2026-07-24",{"name":311,"class":76},"Centre Hospitalier Universitaire de la Réunion",4]